39
Transthyretinand ISIS-TTR
Rx
We obtained issued claims covering ISIS-TTR
Rx
in theUnitedStates. The issuedU.S. claims shouldprotect ISIS-TTR
Rx
fromgeneric competition in theUnitedStates until at least 2025. We are alsopursuing additional patent applications designed to
protect ISIS-TTR
Rx
in theUnitedStates andother foreign jurisdictions, includingEurope and Japan. The table below lists the current
issuedU.S. patent protecting ISIS-TTR
Rx
:
Jurisdiction
PatentNo.
Title
Expiration
DescriptionofClaims
UnitedStates........
8,101,743
MODULATIONOF
TRANSTHYRETIN
EXPRESSION
2025
Antisense sequence and chemistry of ISIS-
TTR
Rx
In some cases, the patent term canbe extended to recapture a portionof the term lost duringFDA regulatory review.
RNAiMotifs andMechanisms - TheCrookePatents
TheCrooke Patents, which are the result of the earlyworkbyDr. Crooke and co-workers exploringoligonucleotides that
activate double-stranded ribonucleases, or dsRNases, cover chemically-modified, RNA-containingoligonucleotides andmethods for
exploiting theRNAi pathwaywith these oligonucleotides until June 2016.We licensed theCrookePatents toAlnylam for the
development of double-stranded therapeutics and toRegulus for the development ofmicroRNA-targeting therapeutics. These patents
alsoprovide uswith exclusivity in the fieldof ssRNAi compounds, inwhichwe havemade great strides toprogress this approach
toward a viable therapeutic platform. The followingpatents have issuedout of theCrookePatent family:
Jurisdiction
PatentNo.
Title
Expiration
DescriptionofClaims
UnitedStates ......
5,898,031
OLIGORIBONUCLEOTIDES
FORCLEAVINGRNA
2016
Oligonucleotides comprising regions of RNA
nucleosides and regions of nucleosides
having stabilizing chemicalmodifications.
Sucholigonucleotides are suitable for use in
single- anddouble-stranded applications.
UnitedStates ......
6,107,094
OLIGORIBONUCLEOTIDES
FORCLEAVINGRNA
2016
Compounds andmethods that use
oligonucleotides havingbothRNA
nucleosides and chemicallymodified
nucleosides, includingmethods that relyon a
dsRNAse to reduce target RNA and
compounds havingnucleosideswith
improved affinity and/or stability.
UnitedStates ......
7,432,249
OLIGORIBONUCLEOTIDES
FORCLEAVINGRNA
2016
Pharmaceutical compositions comprising a
diluent or carrier and a single-stranded
antisense oligonucleotide having a plurality
ofRNAnucleosides and at least one sugar
modification.
UnitedStates ......
7,432,250
OLIGORIBONUCLEOTIDES
FORCLEAVINGRNA
2016
Methods for treating a patient by
administering an antisense compoundhaving
a plurality ofRNA nucleosides and at least
one sugarmodification.
UnitedStates ......
7,629,321
OLIGORIBONUCLEOTIDES
FORCLEAVINGRNA
2016
Methods for cleaving a target RNA in a cell
by contacting the cell with a single-stranded
antisense compoundhaving a pluralityof
RNAnucleosides and at least one sugar
modification.
UnitedStates ......
7,695,902
OLIGORIBONUCLEOTIDES
FORCLEAVINGRNA
2016
Methods of activating a dsRNase by
contacting the dsRNasewith a double-
stranded antisense oligonucleotidewhere at
least one strandhas a pluralityofRNA
nucleosides and at least one sugar
modification. Themethodsmaybe performed
inside a cell.
